| Assessment Status | Rapid Review Complete |
| HTA ID | 25019 |
| Drug | Bimekizumab |
| Brand | Bimzelx® |
| Indication | • For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs. • For the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. |
| Assessment Process | |
| Rapid review commissioned | 06/03/2025 |
| Rapid review completed | 03/04/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that bimekizumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.
